Announcement PDF CLEARVUE TECHNOLOGIES LIMITED AND ITS CONTROLLED ENTITIES ABN 45 071 397 487 Appendix 4E 1. Company details Name of entity: ABN: Reporting period: Previous period: ClearVue Technologies Limited 45 071 397 487 For the year ended 30 June 2025 For the year ended 30 June 2024 2. Results for announcement to the market Revenues from ordinary activities $ up 553% to 249,925 Loss from ordinary activities after tax attributable to the owners of Clearvue Technologies Limited down 7% to 11,584,706 Loss for the year attributable to the owners of Clearvue Technologies Limited down 7% to 11,584,706 Dividends No dividend has been declared or paid for the year ended 30 June 2025(30 June 2024: $nil). Brief Explanation of Results For fiscal year 2025 ClearVue revenue from ordinary activities increased by 553% to $249,925. Net loss after tax was cut by 7% to 11,584,706. Fiscal year 2025 laid the foundation for global commercialization with several product advancements and announcements, new strategic partnerships, new license partner agreements and noteworthy projects In October 2024, ClearVue executed an equity placement raising approximately $7.5 million. Product Advancements and Announcements: • October 2024: ClearVue won the Best of Greenbuild 2024 as the most innovative solution. • October 2024: ClearVue was named a finalist (one in 8 out of over 6,000 submissions) at the Hong Kong Green Building Tech Challenge. The program was a joint initiative between Carbonless Asia and the Hong Kong Science and Technology Parks Corporation. • June 2024: ClearVue introduced the Integrated Solar Façade, an expanded solar product suite, including solar spandrel, solar cladding, and architectural BIPV skylight and balustrade glass. The product line expansion resulted in broad options for deployment of solar energy generating solutions across the entire building envelope. Strategic Partnerships: • April 2025: ClearVue signed a non-binding MOU with LandVac (LandGlass subsidiary) to jointly research, develop, manufacture, and commercialize solar vacuum-insulated glazing (Solar VIG). The product advancement will combine thermal insulation and solar generation capabilities across the ClearVue product line including vacuuminsulated vision glass, skylights, spandrel and cladding. The resulting solutions will be co-branded and marketed via both parties’ global distribution networks through a new Hong Kong-based joint venture which will hold the IP. • November 2024, ClearVue signed a five-year OEM agreement with Maxblue Industrial Glass in China which expanded the Company’s supply chain flexibility and capacity to support large-scale or licensee-based global deployments. License Partner Agreements: . • May 2025: ClearVue secured a five-year exclusive manufacturing and distribution agreement with New Zealandbased Viridian Glass, enabling local production of IGUs and the full ClearVue BIPV range including spandrel, skylights, and cladding. This partnership facilitates better accessibility for CleanTech buildings in New Zealand. • April 2025: ClearVue expanded into the South Korean market via a partnership with Sinrok Solar Energy. ClearVue appointed Sinrok as its exclusive partner for securing the development and delivery of the Bara Factories Expansion Project. • August 2024: ClearVue executed a five-year licensing agreement with Alutec, Qatar's largest glass and façade maker, to manufacture and distribute ClearVue’s BIPV products across Qatar, UAE, Saudi Arabia, and India. CLEARVUE TECHNOLOGIES LIMITED AND ITS CONTROLLED ENTITIES ABN 45 071 397 487 Appendix 4E Noteworthy Projects: • May 2025: ClearVue a high-rise commercial installation at Sydney’s Tattersalls Club was announced with plans to install BIPV feature glass across floors 44–50. The installation of ClearVue solutions will enhance energy efficiency and contribute to a 6-star NABERS rating. As recently announced, compatibility testing for silicon seal and laminate was underway. • April 2025: ClearVue secured a solar skylight project to be installed on the new World Bank building in Abuja, Nigeria. ClearVue delivered 100 units (~140 W/m²), valued at ~USD 64,000, with estimated annual generation of 37,800 kWh. This project marked ClearVue’s entry into the African market via Venco Imtiaz (Dubai). As announced in an update, the double-glazed skylight units have been manufactured, framed and were in transit. • October 2024: ClearVue Solar Façade cladding sections were planned for installation on sections of Enex100 at 100 St Georges Terrace in Perth, Australia. As announced in a project update, the panels have been delivered, and installation had begun. • September 2024: ClearVue entered the modular housing market and secured a first order for solar glazing and integrated solar cladding to Australia-based Prefabulous. The units are ready for installation. • June of 2024, ClearVue announced planned installation of nine solar window units at a Leicester Street facility in Melbourne, which is expected to generate up to 400 Wp, offering up to 30 W/m², and reducing solar heat gain by 22.8% while maintaining 70% visible light. The installation is estimated to deliver 94.8 kg of carbon savings annually. Highlights: • Geographic Expansion: Secured manufacturing and distribution partnerships across key markets including Middle East, China, New Zealand, South Korea and Africa. This positions ClearVue for scalable, low-capex expansion. • Product Maturation & Market Credibility: Successful deployments have begun including a high-rise façade in Sydney and skylights for the World Bank in Nigeria which demonstrated ClearVue product adaptability, aesthetic integration, regulatory compliance (fire rating) and energy performance. • R&D Investment & Validation: Tax incentives and consortia involvement underscore a deepening innovation pipeline which underpins the long-term technology leadership ClearVue has in BIPV solutions. • Commercialisation: ClearVue has an increasing project inquiry rate including prototype deployments, regulatory trials and global agreements which will support continued revenue growth. Additional strategic partnerships and licensing agreements will support revenue growth as well. No other significant changes occurred in the nature of the Company's activities during the financial year. The loss for the consolidated entity after providing for income tax amounted to $11,662,162 (30 June 2023 $12,491,037). 3. Net tangible assets Reporting period Cents Net tangible assets per ordinary security 1.11 Previous period Cents 1.79 CLEARVUE TECHNOLOGIES LIMITED AND ITS CONTROLLED ENTITIES ABN 45 071 397 487 Appendix 4E 4. Details of associates and joint venture entities Name ClearVue International Pty Ltd ClearVue USA Inc ClearVue (Asia) Pte.Ltd ClearVue Europe BV Clearvue Europe Holdings BV Opticrop (Israel) Ltd Country of Incorporation Australia United States of America Singapore Netherlands Netherlands Isreal Ownership Interest 2025 2024 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% na 5. Details of entities over which control has been gained or lost during the period NA 6. Audit qualification or review Details of audit/review dispute or qualification (if any): The financial statements are in the process of being audited. 7. Attachments Details of attachments (if any): The Preliminary Financial Report of ClearVue Technologies Limited for the year ended 30 June 2024 is attached. 8. Signed Theresa Smits Interim Chairperson Perth Date: 29 August 2025 CLEARVUE TECHNOLOGIES LIMITED AND ITS CONTROLLED ENTITIES ABN 45 071 397 487 Appendix 4E CLEARVUE TECHNOLOGIES LIMITED AND ITS CONTROLLED ENTITIES ABN 45 071 397 487 Appendix 4E Preliminary Financial Report 30 June 2025 CLEARVUE TECHNOLOGIES LIMITED AND ITS CONTROLLED ENTITIES ABN 45 071 397 487 CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE YEAR ENDED 30 JUNE 2025 Note Revenue from contracts with customers Other income Expenses Consulting expense Depreciation and amortisation expense Employee benefits expense Finance costs Legal fees Impairment Material costs Share-based payments expense Product Development testing Travel expenses Other expenses 8 Loss before income tax Income tax expense Loss for the year Other comprehensive income / (loss) Total comprehensive loss for the year Loss per share attributable to the owners of the Company (cents) Basic loss per share Diluted loss per share 9 9 Consolidated 30 Jun 2025 $ Consolidated 30 Jun 2024 $ 249,925 910,041 1,159,966 39,811 1,193,266 1,233,077 (3,167,310) (524,998) (3,281,565) (33,135) (211,256) (786,363) (1,084,439) (526,492) (364,186) (712,759) (2,052,169) (12,744,672) (3,495,291) (630,190) (2,371,850) 23,025 (124,721) (719,377) (3,843,240) (472,231) (746,826) (1,343,413) (13,724,114) (11,584,706) (12,491,037) - - (11,584,706) (12,491,037) - - (11,584,706) (12,491,037) (4.5) (4.5) (5.4) (5.4) See accompanying notes to the consolidated financial statements 1 CLEARVUE TECHNOLOGIES LIMITED AND ITS CONTROLLED ENTITIES ABN 45 071 397 487 CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 30 JUNE 2025 Consolidated 30 Jun 2025 $ Consolidated 30 Jun 2024 $ 3,591,254 1,009,027 711,476 5,311,757 3,554,485 1,144,841 522,866 5,222,192 525,210 472,517 6,052,189 144,496 7,194,412 521,194 567,020 5,967,549 75,685 7,131,448 12,506,169 12,353,640 2,421,116 80,664 241,319 2,743,099 1,476,320 75,396 170,551 1,722,267 410,961 101,875 512,836 491,624 70,842 562,466 Total Liabilities 3,255,235 2,284,733 Net Assets 9,250,235 10,068,907 51,349,503 8,624,453 (50,723,721) 41,021,685 8,596,507 (39,545,637) 9,250,235 10,068,907 Note ASSETS Current Assets Cash and cash equivalents Trade and other receivables Other assets 2 3 Non-Current Assets Plant and equipment Right of use asset Intangible assets Other assets 4 Total Assets LIABILITIES Current Liabilities Trade and other payables Lease liabilities Provisions 5 Non-Current Liabilities Lease liabilities Provisions EQUITY Share capital Share-based payments reserve Accumulated losses 6 7 Total Equity See accompanying notes to the consolidated financial statements 2 CLEARVUE TECHNOLOGIES LIMITED AND ITS CONTROLLED ENTITIES ABN 45 071 397 487 CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 30 JUNE 2025 Share-Based Payments Accumulated Reserve Losses $ $ Share Capital $ Balance at 1 July 2023 Total $ 32,360,091 6,039,351 (27,677,121) 10,722,321 - - (12,491,037) (12,491,037) (12.491,037) (12,491,037) 120,439 - 582,798 39,723 219,849 1,569,863 2,053,528 8,440,360 (464,727) 18,750 Loss for the year Other comprehensive income Total comprehensive loss for the year Share based payments Performance rights issued Options issued Options exercised Options expired Ordinary shares issued Share issue costs Director’s loan repaid 565,522 8,440,360 (464,727) - 99,410 1,569,863 2,053,528 (565,522) (582,798) (20,973) Balance at 30 June 2024 41,021,685 8,592,859 (39,545,637) 10,068,907 - - (11,584,706) (11,584,706) (11,584,706) (11,584,706) 88,278 - 134,863 195,596 76,162 - 187,688 338,805 3,392,900 7,500,000 (653,360) (50,723,721) 9,250,235 Loss for the year Other comprehensive income Total comprehensive loss for the year Share based payments Performance rights exercised Options issued Options exercised Options expired Ordinary shares issued Share issue costs 3,392,900 7,500,000 (653,360) 99,410 (134,863) 338,805 (195,596) (76,162) - Balance at 30 June 2025 51,349,503 8,624,453 See accompanying notes to the consolidated financial statements 3 CLEARVUE TECHNOLOGIES LIMITED AND ITS CONTROLLED ENTITIES ABN 45 071 397 487 CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 30 JUNE 2025 Note Consolidated 30 Jun 2025 $ Consolidated 30 Jun 2024 $ Cash flows from operating activities Receipts from customers and others Payments to suppliers, employees and others Interest received Interest paid Net cash (used in) operating activities 1,369,251 (10,653,467) 52,342 (9,231,873) 1,097,072 (9,024,633) 23,025 (7,904,536) Cash flows from investing activities Patents and trademarks expenditure Development expenditure Purchase of plant and equipment Net cash (used in) investing activities (1,241,998) (62,436) (1,304,434) (830,469) (408,877) (256,504) (1,495,850) Cash flows from financing activities Options exercised Ordinary shares issued Share issue costs Loan proceeds Director loan repaid Lease payments Net cash from financing activities 3,392,900 7,500,000 (654,440) 409,159 (75,396) 10,572,224 561,875 7,878,485 (464,727) 18,750 (189,675) 7,804,708 35,917 (1,595,678) 852 (14,500) Cash and cash equivalents at beginning of year 3,554,485 5,164,663 Cash and cash equivalents at end of year 3,591,254 3,554,485 Net (decrease) in cash and cash equivalents Effects of currency translation on cash See accompanying notes to the consolidated financial statements 4 CLEARVUE TECHNOLOGIES LIMITED AND ITS CONTROLLED ENTITIES ABN 45 071 397 487 NOTES TO CONSOLIDATED PRELIMINARY FINANCIAL REPORT FOR THE YEAR ENDED 30 JUNE 2025 These notes form an integral part of and should be read in conjunction with the accompanying financial report: 1. BASIS OF PREPARATION This preliminary financial report has been prepared in accordance with Australian Securities Exchange Listing Rules as they relate to the Appendix 4E and in accordance with the recognition and measurement requirements of the Australian Accounting Standards, other authoritative pronouncements of the Australian Accounting Standards Board, Urgent Issues Group Interpretations and the Corporations Act 2001. As such, this preliminary financial report does not include all the notes of the type included in an annual financial report and accordingly, should be read in conjunction with the annual report for the year ended 30 June 2024 and with any public announcement made by Clearvue Technologies Limited during the period in accordance with the continuous disclosure requirements of the Corporations Act 2001. The principal accounting policies adopted in the preparation of the financial report are consistent with those of the previous financial year. 2. CASH AND CASH EQUIVALENTS Cash and cash equivalents 3. Consolidated 30 Jun 2025 $ Consolidated 30 Jun 2024 $ 3,560,837 3,554,485 Consolidated 30 Jun 2025 $ Consolidated 30 Jun 2024 $ 140,740 868,287 1,009,027 40,558 1,104,283 1,144,841 TRADE AND OTHER RECEIVABLE Trade receivables R&D rebate receivable 5 CLEARVUE TECHNOLOGIES LIMITED AND ITS CONTROLLED ENTITIES ABN 45 071 397 487 NOTES TO CONSOLIDATED PRELIMINARY FINANCIAL REPORT FOR THE YEAR ENDED 30 JUNE 2025 4. INTANGIBLE ASSETS Consolidated 30 Jun 2025 $ Patents and trademarks Development asset Consolidated 30 Jun 2024 $ 3,665,114 2,387,075 6,052,189 3,378,822 2,588,727 5,967,549 Patents and trademarks Cost Less impairment Less accumulated amortisation Carrying amount 5,546,497 (786,363) (1,095,020) 3,665,114 4,304,500 (925,678) 3,378,822 Cost Balance at 1 July Additions1 Balance at 30 June 4,304,500 1,241,997 5,546,497 3,474,030 830,470 4,304,500 Accumulated amortisation Balance at 1 July Amortisation for the year Balance at 30 June 925,678 169,342 1,095,020 678,158 247,520 925,678 Carrying amount at 30 June 3,665,114 3,378,822 Development asset Cost Less accumulated amortisation Carrying amount 2,787,573 (400,498) 2,387,075 2,787,573 (198,846) 2,588,727 Cost Balance at 1 July Additions Balance at 30 June 2,787,573 2,787,573 2,378,696 408,877 2,787,573 Accumulated amortisation Balance at 1 July Amortisation for the year Balance at 30 June 198,846 201,652 400,498 59,467 139,379 198,846 Carrying amount at 30 June 2,387,075 2,588,727 Net carrying amount at 30 June 6,052,189 5,967,549 Intangible assets are stated at cost. The useful life of these patents and trademarks is estimated to be finite. Impairments were recognised during the financial year with IP associated with Lusoco and Opticrop were impaired to nil (2024: nil). 6 CLEARVUE TECHNOLOGIES LIMITED AND ITS CONTROLLED ENTITIES ABN 45 071 397 487 NOTES TO CONSOLIDATED PRELIMINARY FINANCIAL REPORT FOR THE YEAR ENDED 30 JUNE 2025 5. TRADE AND OTHER PAYABLES Consolidated 30 Jun 2025 $ Consolidated 30 Jun 2024 $ 1,031,016 255,614 300,000 110,709 409,159 314,618 2,421,116 683,147 167,532 300,000 115,125 210,516 1,476,320 Trade payables Prepaid revenue Unacquitted Grant Other payables Loan Radium Capital Accruals 6. SHARE CAPITAL 30-Jun-25 NO. OF SHARES 30-Jun-24 NO. OF SHARES 30-Jun-25 30-Jun-24 $ $ 242,658,474 33,437,500 454,193 1,575,000 217,171,757 12,307,000 10,254,717 2,925,000 41,021,685 7,500,000 88,278 322,500 32,360,091 8,440,360 120,439 565,522 500,000 - - - - - (653,360) (464,727) 278,625,167 242,658,474 51,349,503 41,021,685 Share issued and fully paid Balance at 1 July Shares issued Share based payments Options Exercised Performance rights exercised Share issue costs Balance at 30 June The share capital of the Company consists only of fully paid ordinary shares; the shares do not have a par value. All shares are equally eligible to receive dividends and the repayment of capital and represent one vote at the shareholders’ meeting of the Company 7 CLEARVUE TECHNOLOGIES LIMITED AND ITS CONTROLLED ENTITIES ABN 45 071 397 487 NOTES TO CONSOLIDATED PRELIMINARY FINANCIAL REPORT FOR THE YEAR ENDED 30 JUNE 2025 7. SHARE-BASED PAYMENTS RESERVE Consolidated 30 Jun 2025 Consolidated 30 Jun 2024 $ $ Opening balance 8,592,859 6,039,351 Performance Rights Issued Options Issued Options Exercised Options expired Share based payment Performance rights exercised Director Loan repaid 338,805 (195,596) (76,162) 99,410 (134,863) - 1,569,863 2,053,528 (565,522) (582,798) 99,410 8,624,453 8,582,859 (20,973) 1 The share plan arises on the grant of loan for a term of 10 years to Directors and related parties for the purchase of the Company’s ordinary shares under the ClearVue Loan Funded Share Plan in 2017. Amounts are transferred out of the reserve and into share capital when the loans are settled. NO. OF OPTIONS NO. OF PERFORMANCE RIGHTS $ Movements in Share based payment reserve Balance at 1 July 2023 Options issued Options exercised Options expired Options vested Director loan repaid Performance rights issued 19,050,000 10,602,262 (2,925,000) (5,000,000) - 10,000,000 5,000,000 6,039.351 2,053,528 (565,522) (582,798) 99,410 (20,973) 1,569,863 Balance at 30 June 2024 21,727,262 15,000,000 8,592,859 NO. OF OPTIONS Movements in Share based payment reserve Balance at 1 July 2024 Options issued Options exercised Options expired Options vested Performance rights Exercised Balance at 30 June 2025 NO. OF PERFORMANCE RIGHTS $ 21,727,262 1,150,000 (1,575,000) (1,150,000) - 15,000,000 (500,000) 8,592,859 338,805 (565,522) (195,596) 99,410 1,569,863 19,752,262 15,000,000 8,624,449 8 CLEARVUE TECHNOLOGIES LIMITED AND ITS CONTROLLED ENTITIES ABN 45 071 397 487 NOTES TO CONSOLIDATED PRELIMINARY FINANCIAL REPORT FOR THE YEAR ENDED 30 JUNE 2025 7. SHARE-BASED PAYMENTS RESERVE – continued Options The following share-based payment arrangements were in place during the current and prior periods: Expiry Number Grant date Vesting Condition date Class CPVAT 1,150,000 05/07/2024 30/06/2027 No vesting Conditions CPVAS 93,333 19/06/2024 19/06/2026 No vesting conditions CPVAR 5,508,929 12/03/2026 No vesting conditions CPVAO3 1,000,000 10/04/2024, 26/03/2024 and 12/03/2024 30/10/2023 30/10/2027 Options vest on the condition the share price of the Company reaches $0.50 and maintains a VWAP of $0.50 for at least 14 days within and prior to the expiry CPVAP2 2,000,000 13/12/2023 13/12/2026 No vesting Conditions 2 2,000,000 13/12/2023 13/12/2026 No vesting conditions CPVAL CPVAM CPVAN 2,500,000 3,000,000 3,000,000 20/06/2023 20/06/2023 23/05/2023 30/11/2025 30/11/2026 12/07/2027 No vesting conditions No vesting conditions The options comprise vesting milestones of 500,000 tranche 1 options (VWAP of $1.00 per share for at least 30 days), 500,000 tranche 2 options (introducing and procuring a strategic alliance), 500,000 tranche 3 options (VWAP of $1.50 per share for at least 30 days), 500,000 tranche 4 options (securing a commercial deployment) and 1,000,000 tranche 5 options (commence up-listing of its OTCQB listing into the NASDAQ). CPVAQ 9 CLEARVUE TECHNOLOGIES LIMITED AND ITS CONTROLLED ENTITIES ABN 45 071 397 487 NOTES TO CONSOLIDATED PRELIMINARY FINANCIAL REPORT FOR THE YEAR ENDED 30 JUNE 2025 7. SHARE-BASED PAYMENTS RESERVE – continued The following table illustrates the number and weighted average exercise prices of and movements in share options issued during the year: 2025 2024 Weighted Weighted average average exercise price exercise price Number $ Number $ Outstanding at the 21,727,262 0.52 19,050,000 0.195 beginning of year Granted during the year 1,150,000 0.55 10,602,262 0.68 Exercised during the year (1,575,000) 0.21 (2,925,000) 0.19 Expired during the year (1,550,000) 0.30 (5,000,000) 0.52 Outstanding at the end of 19,752,262 0.56 21,727,262 0.52 year Exercisable at the end of 12,752,262 0.58 14,727,262 0.51 year The fair value of the equity-settled share options listed above is estimated as at the date of grant using the Black-Scholes model taking into account the terms and conditions upon which the options were granted The expected life of the options is based on historical data and is not necessarily indicative of exercise patterns that may occur. The expected volatility reflects the assumption that the historical volatility is indicative of future trends, which may also not necessarily be the actual outcome. No other features of options granted were incorporated into the measurement of fair value 10 CLEARVUE TECHNOLOGIES LIMITED AND ITS CONTROLLED ENTITIES ABN 45 071 397 487 NOTES TO CONSOLIDATED PRELIMINARY FINANCIAL REPORT FOR THE YEAR ENDED 30 JUNE 2025 7. SHARE-BASED PAYMENTS RESERVE – continued The conversion of the performance rights is dependent on the following: (i) (ii) (iii) Class A Performance Rights (A) In the event that the aggregate of the value of the ClearVue (Orders and the ClearVue Payments is equal to or greater than $2,000,000 within a period of 24 months commencing on the date of issue of the Performance Rights (Issue Date) (Class A Milestone 1), each Class A Performance Right will vest and be convertible into one Share; or (B) in the event that Class A Milestone 1 is not satisfied but the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than $7,000,000 within a period of 36 months from the Issue Date (Class A Milestone 2), each Class A Performance Right will vest and be convertible into one Share; or (C) in the event that neither Class A Milestone 1 or Class A Milestone 2 is satisfied but the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than $17,000,000 within a period of 48 months from the Issue Date, each Class A Performance Right will vest and be convertible into one Share. Class B Performance Rights (A) In the event that the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than $5,000,000 within a period of 24 to 36 months from the Issue Date (Class B Milestone 1), each Class B Performance Right will vest and be convertible into one Share; or (B) in the event that Class B Milestone 1 is not satisfied but the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than $7,000,000 within a period of 36 months from the Issue Date (Class B Milestone 2), each Class B Performance Right will vest and be convertible into one Share; or (C) in the event that neither Class B Milestone 1 or Class B Milestone 2 is satisfied but the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than $17,000,000 within a period of 48 months from the Issue Date, each Class B Performance Right will vest and be convertible into one Share. Class C Performance Rights (A) In the event that the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than $10,000,000 within a period of 36 to 48 months from the Issue Date (Class C Milestone 1), each Class C Performance Right will vest and be convertible into one Share; or (B) In the event that Class C Milestone 1 is not satisfied but the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than $17,000,000 within a period of 48 months from the Issue Date, each Class C Performance Right will vest and be convertible into one Share. 11 CLEARVUE TECHNOLOGIES LIMITED AND ITS CONTROLLED ENTITIES ABN 45 071 397 487 NOTES TO CONSOLIDATED PRELIMINARY FINANCIAL REPORT FOR THE YEAR ENDED 30 JUNE 2025 7. SHARE-BASED PAYMENTS RESERVE – continued (iv) Class D Performance Rights (A) (v) Class E Performance Rights (A) (vi) In the event the share price for the ordinary shares of the company reaches $0.50 and maintains a volume weighted average of $0.50 per ordinary share for at least 14 days with and before the expiry date , each of the class H performance rights will vest and be convertible into a share Class I Performance Rights (A) (x) In the event that the participant assists the company to complete an up-listing of its OTCQB US or ASX listing into the main US board of the NASDAQ or the NYSE before the expiry date or have commenced at least 3 months before the expiry date and such up-listing is completed within a further 6 months after the end of the expiry date, each of the class G performance rights will vest and be convertible into a share Class H Performance Rights (A) (ix) In the event that the participant introduces an equity investor to the company where the equity investment transaction is concluded and / or the participant has carriage of concluding an equity investment transaction before the expiry date, each of the class E performance rights will vest and be convertible into a share Class G Performance Rights (A) (viii) In the event that the participant introduces an equity investor to the company where the equity investment transaction is concluded and / or the participant has carriage of concluding an equity investment transaction before the expiry date, each of the class E performance rights will vest and be convertible into a share. Class F Performance Rights (A) (vii) In the event that the participant assisting the company completes the development and testing of vision and spandrel glass to achieve an A2 SO D1 fire rating confirmed by an independent third party testing, with such testing party approved by the company and certified to the EN13501.1 standard before the expiry date, each class D performance right will vest and be convertible into a share. In the event that the company receives revenue of AUD$1,500,000 from the sale of its own products (incorporating the ClearVue technology) during a twelve-month period before the expiry date, each of the class E performance rights will vest and be convertible into a share Class J Performance Rights (A) In the event that the company receives revenue of AUD$1,500,000 from the sale of its own products (incorporating the ClearVue technology) during a twelve-month period before the expiry date, each of the class E performance rights will vest and be convertible into a share 12 CLEARVUE TECHNOLOGIES LIMITED AND ITS CONTROLLED ENTITIES ABN 45 071 397 487 NOTES TO CONSOLIDATED PRELIMINARY FINANCIAL REPORT FOR THE YEAR ENDED 30 JUNE 2025 7. SHARE-BASED PAYMENTS RESERVE – continued The fair value of the performance rights is estimated as at the date of grant using the Black-Scholes model taking into account the terms and conditions upon which the rights were granted. The performance requirements are non-vesting conditions as there is no service requirement and therefore the fair value was expensed immediately. 8. SHARE-BASED PAYMENTS EXPENSE Shares issued to consultants Options issued to consultants Performance rights issued Options issued to Directors Options issued to employees 9. Consolidated 30 Jun 2025 $ Consolidated 30 Jun 2024 $ 88,278 438,214 526,492 120,439 263,101 1,569,863 1,490,943 398,894 3,843,240 Consolidated 30 Jun 2025 $ Consolidated 30 Jun 2024 $ (11,584,706) (12,492,232) No. 259,491,780 No. 229,607,059 LOSS PER SHARE Loss after income tax used in calculating basic and diluted earnings per share Weighted average number or ordinary shares used in calculating basic and diluted earnings per share Cents (4.5) (4.5) Basic loss per share Diluted loss per share 13 Cents (5.4) (5.4)